Xujun J. You

Shenzhen, 518133, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation.

An E3 Aptamer-Modified T Cell-Derived Exosomal Nanoplatform for Codelivery of Astragaloside IV and PESV: Enhancing Prostate Cancer Therapy Through Immune Modulation with Implications for Clinical Translation.

Journal: International journal of nanomedicine

Published: April 17, 2026

Corrigendum to "Xihuang pills targeting the Warburg effect through inhibition of the Wnt/β-catenin pathway in prostate cancer" [Heliyon Volume 10, Issue 12, June 2024, Article e32914].

Corrigendum to "Xihuang pills targeting the Warburg effect through inhibition of the Wnt/β-catenin pathway in prostate cancer" [Heliyon Volume 10, Issue 12, June 2024, Article e32914].

Journal: Heliyon

Published: November 11, 2025

Hedyotis diffusae herba -Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis.

Hedyotis diffusae herba -Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis.

Journal: Scientific reports

Published: August 22, 2025

Effect and mechanism of tigecycline on proliferation of liver tumor cells in mouse model

Effect and mechanism of tigecycline on proliferation of liver tumor cells in mouse model

Journal: Zhonghua yi xue za zhi

Published: July 07, 2025

Combination of astragalus polysaccharide with Diosbulbin B exerts an enhanced antitumor effect in BRAFmut papillary thyroid cancer with decreased liver toxicity.

Combination of astragalus polysaccharide with Diosbulbin B exerts an enhanced antitumor effect in BRAFmut papillary thyroid cancer with decreased liver toxicity.

Journal: Cancer cell international

Published: December 17, 2024

Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1.

Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: October 31, 2024

Corrigendum: Astragalus-Scorpion drug pair inhibits the development of prostate cancer by regulating GDPD4-2/PI3K/AKT/mTOR pathway and autophagy.

Corrigendum: Astragalus-Scorpion drug pair inhibits the development of prostate cancer by regulating GDPD4-2/PI3K/AKT/mTOR pathway and autophagy.

Journal: Frontiers in pharmacology

Published: April 15, 2024

Author Correction: Exploring the mechanism of action of Sparganii Rhizoma-Curcumae Rhizoma for in treating castration-resistant prostate cancer: a network-based pharmacology and experimental validation study.

Author Correction: Exploring the mechanism of action of Sparganii Rhizoma-Curcumae Rhizoma for in treating castration-resistant prostate cancer: a network-based pharmacology and experimental validation study.

Journal: Scientific reports

Published: March 01, 2024

Feasibility study of lncRNA DHRS4-AS1 sponge miR-222-3p in the diagnosis of thyroid cancer.

Feasibility study of lncRNA DHRS4-AS1 sponge miR-222-3p in the diagnosis of thyroid cancer.

Journal: Endokrynologia Polska

Published: February 20, 2024

Xihuang pills targeting the Warburg effect through inhibition of the Wnt/β-catenin pathway in prostate cancer.

Xihuang pills targeting the Warburg effect through inhibition of the Wnt/β-catenin pathway in prostate cancer.

Journal: Heliyon

Published: December 03, 2023

Exploring the mechanism of action of Sparganii Rhizoma-Curcumae Rhizoma for in treating castration-resistant prostate cancer: a network-based pharmacology and experimental validation study.

Exploring the mechanism of action of Sparganii Rhizoma-Curcumae Rhizoma for in treating castration-resistant prostate cancer: a network-based pharmacology and experimental validation study.

Journal: Scientific reports

Published: November 21, 2023

Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.

Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.

Journal: BMC cancer

Published: August 03, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026